Medtronic
Medtronic Completes Enrollment of Extreme Risk Patient Group in CoreValve U.S. Pivotal Trial
January 25, 2012 5:50 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation...
First Patient Enrolled in Medtronic-Supported Head-to-Head Clinical Trial Comparing Cryoballoon Ablation to RF Ablation for Paroxysmal Atrial Fibrillation
January 25, 2012 5:46 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized, multinational head-to-head clinical trial comparing the long-term safety, effectiveness and ease of use of the Medtronic Arctic...
Medtronic Announces 510(k) Clearance for the Aquamantys SBS 5.0 Sheathed Bipolar Sealer for Spine Surgery
January 24, 2012 4:44 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company's Advanced Energy business.
Medtronic Launches First-of-Its-Kind mySentry Remote Glucose Monitor
January 5, 2012 5:12 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Today, Medtronic, Inc. announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentryâ„¢ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient's MiniMed...
Data Shows Medtronic AdaptiveStim with RestoreSensor Provides Pain Relief and Convenience
December 12, 2011 4:51 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStimâ„¢ with RestoreSensorâ„¢ neurostimulation system from Medtronic provides clinical benefits for many patients...
FDA Advisory Panel Recommends Expanded Indication for Medtronic Cardiac Resynchronization Therapy with Defibrillator (CRT-D) Devices
December 9, 2011 5:35 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices Advisory Panel determined that the overall clinical benefits of Medtronic cardiac resynchronization therapy...
Medtronic Receives FDA Approval for Next Generation Professional Continuous Glucose Monitoring
November 23, 2011 6:11 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals...
Medtronic Receives FDA Approval of Adaptivestim with Restoresensor for the Management of Chronic Pain
November 23, 2011 5:59 am | News | CommentsMINNEAPOLIS – November 17, 2011 – Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™ neurostimulation system, the first and only chronic pain treatment that harnesses motion sensor technology...
Retrospective Study Shows New Device Significantly Reduces Blood Loss and Transfusions in Adolescent Scoliosis Corrective Surgery
November 10, 2011 5:45 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal Disorders and Techniques that demonstrates the effectiveness of the Aquamantys® System...
Medtronic Begins Enrolling U.S. IDE Study of EnliteTM Sensor for Continuous Glucose Monitoring
November 10, 2011 5:19 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enliteâ„¢ Sensor, the company's latest innovation in continuous glucose monitoring...
Study of Medtronic Endeavor® Drug-Eluting Stent Demonstrates Long-Term Advantages over Taxus® DES
November 9, 2011 4:26 am | News | CommentsSAN FRANCISCO--(BUSINESS WIRE)--New research findings released at TCT 2011 show that the Endeavor® zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed Boston Scientific Corp.'s Taxus® paclitaxel-eluting stent on standard measures of safety and efficacy through five years of clinical follow-up.
Medtronic CoreValve® System Gains CE Mark for New Direct Aortic Approach to Transcatheter Aortic Valve Implantation
November 8, 2011 4:54 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Medtronic CoreValve® System to be delivered using direct aortic access. The Medtronic CoreValve System is now the only transcatheter aortic valve implantation (TAVI) system...
Medtronic Announces Global Launch of the T2 ALTITUDEâ„¢ Expandable Corpectomy Device
November 4, 2011 6:27 am | News | CommentsMEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) announced the global launch of the T2 ALTITUDEâ„¢ Expandable Corpectomy Device in the U.S. and Europe today at the North American Spine Society's 26th Annual Meeting in Chicago.
Medtronic Introduces New Procedure for Minimally Invasive Spinal Fusion
November 2, 2011 8:16 pm | News | CommentsMEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced today a pioneering approach to minimally invasive spinal fusion at the 26th annual meeting of the North American Spine Society in Chicago, IL.
Medtronic Begins Transcatheter Aortic Valve Trial in Japan
November 2, 2011 8:09 pm | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the first implant in a clinical trial in Japan that will evaluate the safety and effectiveness of the Medtronic CoreValve® System. The successful procedure in the trial was led by Professor Yoshiki Sawa
Medtronic Receives First FDA Approval of Cobalt Chromium Balloon-Expandable Stent to Treat Narrowed Iliac Arteries
October 31, 2011 9:14 am | News | CommentsMINNEAPOLIS –– Oct. 31, 2011 –– Advancing the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant® Cobalt Iliac Balloon-Expandable Stent System.
FDA Advisory Panel Makes Recommendation on Investigational Medtronic Phased RF Ablation System for Treatment of Persistent or Long-Standing Persistent Atrial Fibrillation
October 28, 2011 7:44 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against the Medtronic Phased RF Ablation System, the first atrial fibrillation ablation therapy under investigation...
Medtronic Named One of the “World's 25 Best Multinational Workplaces"
October 28, 2011 7:41 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced today The Great Place to Work Institute® included the company on the inaugural “World's 25 Best Multinational Workplaces†list published by FORTUNE magazine.
Medtronic Receives IDE Approval to Conduct ASPIRE In-Home Study of First Insulin Pump with Low Glucose Suspend for US Market
October 28, 2011 7:36 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol...
Medtronic Starts Landmark Study of Hypertension Treatment
October 27, 2011 11:36 am | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity® Renal Denervation System™ for treatment-resistant hypertension. The first patient in this landmark study was enrolled at the Prairie Heart Institute at St. John's Hospital in Springfield, Ill.
Medtronic probes insulin pump risks
October 27, 2011 6:15 am | News | Comments(Reuters) - Medtronic Inc has asked software security experts to investigate the safety of its insulin pumps, as a new claim surfaced that at least one of its devices could be hacked to dose diabetes patients with potentially lethal amounts of insulin. While there are no known examples of such a cyber attack on a medical device, Medtronic told Reuters that it was doing "everything it can" to address the security flaws.
Medtronic 1Q net income climbs to $830 million
August 24, 2010 3:45 am | by The Associated Press | News | CommentsMedical device maker Medtronic says its first-quarter earnings jumped to $830 million, but revenue fell in a soft global health care market.The world's largest medical-device company says it earned 76 cents per share in the three months that ended July 30. That compares to net income of $445...
ATS Medical shareholders approve sale to Medtronic
August 5, 2010 12:45 pm | by The Associated Press | News | CommentsHeart device maker ATS Medical Inc. said Thursday its shareholders have approved the company's $350 million sale to Medtronic Inc., the world's largest medical device maker. ATS Medical said it held a shareholder meeting Thursday, and stockholders owning 61.3 million shares — or 75.3 percent of...
FDA panel recommends Medtronic spinal implant
July 28, 2010 10:45 am | by The Associated Press | News | CommentsA Food and Drug Administration advisory panel has recommended clearance for Medtronic's spin implant Amplify.The FDA's Orthopedic and Rehabilitation Devices Panel vote 6-to-5 in favor of the device, which stimulates bone growth in spinal surgery patients. The FDA normally follows the advice of...
Medtronic reiterates fiscal 2011 earnings guidance
June 23, 2010 7:45 am | by The Associated Press | News | CommentsMedical device maker Medtronic Inc. on Wednesday reiterated its fiscal 2011 earnings guidance and issued a forecast for its first quarter, which ends July 30.At an investor event in Boston on Wednesday, Chief Financial Officer Gary Ellis said the company still expects fiscal 2011 earnings per...
